The New Drug Discovery Center accelerates lead compound identification using an AI-driven predictive system and Computer-Aided Drug Design (CADD) technology for novel compound design, efficacy prediction, and drug-likeness evaluation. Utilizing state-of-the-art equipment such as Microwave Reactors, MPLC, V-10 Touch, and LC-Mass, we synthesize new compounds and optimize leads through structure-activity relationship (SAR) analysis, ultimately identifying promising fibrosis treatment candidates with global market potential.

The New Drug Evaluation Center leverages decades of drug development expertise to assess the in vitro and in vivo activity of candidate compounds, validating their efficacy at both the cellular and animal levels while elucidating their pharmacological mechanisms. Additionally, to secure differentiated compounds for target diseases, we conduct ADME profiling, species-specific pharmacokinetic studies, full ADME analysis, and toxicity evaluations.